Advances in Musculoskeletal and Neuromuscular Rehabilitation
Vol. 34 No. 3 (2024)
Making a difference
“Serendipity favors the prepared mind.” - Louis Pasteur
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 1 August 2024
673
Views
306
Downloads
13
HTML
Authors
This is a personal account of one academic scientist who founded two biotechnology companies. Both companies were initially incubated within the walls of the university under a creative student incubator program whereby biology students could pursue their graduate academic degrees while gaining valuable biotechnology experiences. After the companies transitioned out of the university environment, the professor and his students pursued diagnostic and therapeutic drug development resulting in the completion of several clinical trials. The value of international scientific collaborations with colleagues at the University of Padova (Italy) is also described.
Downloads
Download data is not yet available.
Citations
Carraro U. Exciting perspectives for Translational Myology in the Abstracts of the 2018Spring PaduaMuscleDays: Giovanni Salviati Memorial - Chapter I - Foreword. Eur J Transl Myol 2018;28:7363. DOI: https://doi.org/10.4081/ejtm.2018.7363
Carraro U. Exciting perspectives for Translational Myology in the Abstracts of the 2018Spring PaduaMuscleDays: Giovanni Salviati Memorial - Chapter II - Abstracts of March 15, 2018. Eur J Transl Myol 2018;28:7364. DOI: https://doi.org/10.4081/ejtm.2018.7364
Carraro U. Exciting perspectives for Translational Myology in the Abstracts of the 2018Spring PaduaMuscleDays: Giovanni Salviati Memorial - Chapter III - Abstracts of March 16, 2018. Eur J Transl Myol 2018;28:7365. DOI: https://doi.org/10.4081/ejtm.2018.7365
Carraro U. Exciting perspectives for Translational Myology in the Abstracts of the 2018Spring PaduaMuscleDays: Giovanni Salviati Memorial - Chapter IV - Abstracts of March 17, 2018. Eur J Transl Myol 2018;28:7366. DOI: https://doi.org/10.4081/ejtm.2018.7366
Visentin B, Vekich J, Sibbald B, et al. Sabbadini. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006:9;225-38. DOI: https://doi.org/10.1016/j.ccr.2006.02.023
Sabbadini, R.A. Targeting sphingosine-1-phosphate for cancer therapy. British J Cancer 2006;95:1131-5. DOI: https://doi.org/10.1038/sj.bjc.6603400
Sabbadini RA. Sphingosine-1-Phosphate Antibodies as Potential Agents in the Treatment of Cancer and Age-related Macular Degeneration. British J Pharmacology Mar 2011;162:1225-38. DOI: https://doi.org/10.1111/j.1476-5381.2010.01118.x
Brizuela L, Martin C, Jeannot P, et al. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. Mol Oncol 2014;8:1181-95. DOI: https://doi.org/10.1016/j.molonc.2014.04.001
Zhang L, Wang X, Bullock AJ, et al. Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer. Clin Cancer Res 2015;21:1925-34 2015 DOI: https://doi.org/10.1158/1078-0432.CCR-14-2031
Crack PJ, Zhang M, Morganti-Kossmann MC, et al. Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. J Neuroinflammation 2014;11:37. DOI: https://doi.org/10.1186/1742-2094-11-37
McDonald W, Jones EE, Wojciak JM, et al. MALDI mapping of lysophosphatidic acid changes after traumatic brain injury: relationship to cellular pathology. Am J Pathol 2018;188:1779-93. DOI: https://doi.org/10.1016/j.ajpath.2018.05.005
Sabbadini RA, Betto R, Teresi A, et al. The effects of sphingosine on sarcoplasmic reticulum membrane calcium release. J Biol Chem 1992;267:15475-85. DOI: https://doi.org/10.1016/S0021-9258(19)49559-8
Sabbadini R, Mc Nutt WM, Jenkins G, et al. Sphingosine is endogenous to cardiac and skeletal muscle. Biochim Biophys Res Comm 1993;193:752-8. DOI: https://doi.org/10.1006/bbrc.1993.1689
Dettbarn C, Betto RG, Salviati P, et al. Modulation of cardiac SR ryanodine receptor by endogenous sphingosine. J Mol Cell Cardiol 1994;26:229-42. DOI: https://doi.org/10.1006/jmcc.1994.1026
Betto R, Teresi A, Turcato F, et al. Sphingosylphosphorylcholine modulates the ryanodine receptor calcium release channel of cardiac sarcoplasmic reticulum membranes. Biochem J 1997;322:327-33. DOI: https://doi.org/10.1042/bj3220327
Comstock KL, Krown KA, Page MT, et al. LPS-induced TNF-alpha release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J Mol Cell Cardiol 1998;30:2761-75. DOI: https://doi.org/10.1006/jmcc.1998.0851
Ligutti J, Nakajima N, Cavalli AL, et al. G protein-coupled receptors, calcium deregulation and apoptosis in the heart. Basic Appl Myol 2000;10:75-6.
Danieli D, Germinario E, Palade P, et al. Skeletal muscle high frequency fatigue: effects of modulators of calcium channels. Biophys J 2000;78:30A.
Cavalli A, O’Brien N, Barlow S, et al. Expression and functional characterization of SCaMPER: A calcium channel of cardiomyocytes. Am J Physiol 2003;284:C780-90. DOI: https://doi.org/10.1152/ajpcell.00382.2002
Deutschman D, Carstens JS, Klepper RL, et al. Predicting coronary artery disease using serum sphingosine-1-phosphate. Am Heart J 2003;146:62-8. DOI: https://doi.org/10.1016/S0002-8703(03)00118-2
Giacalone MA, Sabbadini RA, Chambers AL, et al. Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery. Vaccine 2006;24:6009-17. DOI: https://doi.org/10.1016/j.vaccine.2006.04.063
Giacalone MJ, Gentile AM, Lovitt BT, et al. The use of bacterial minicells to transfer plasmid DNA to eukaryotic cells. Cell Microbiol 2006;8:1624-33. DOI: https://doi.org/10.1111/j.1462-5822.2006.00737.x
Giacalone MJ, Zapata JC, Berkley NL, et al. Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus. Vaccine 2007;25:2279-87. DOI: https://doi.org/10.1016/j.vaccine.2006.11.069
Sabbadini R, Scales D, Inesi G. Calcium transport and assembly of protein particles in sarcoplasmic reticulum membranes isolated from normal and dystrophic muscle. FEBS Letters l975;54:8-12. DOI: https://doi.org/10.1016/0014-5793(75)81056-8
Sabbadini R, Baskin RJ. The active state of normal and dystrophic mouse muscle. Am J Physiology l976;230:ll38-49.
O'Brien N, Jones ST, Williams DG, et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res 2009;50:2245-57. DOI: https://doi.org/10.1194/jlr.M900048-JLR200
Goldshmit Y, Matteo R, Sztal T, et al. Blockage of lysophosphatidic acid signalling improves spinal cord injury outcomes. Am J Pathol 2012;181:978-92. DOI: https://doi.org/10.1016/j.ajpath.2012.06.007
How to Cite
Making a difference: “Serendipity favors the prepared mind.” - Louis Pasteur. (2024). European Journal of Translational Myology, 34(3). https://doi.org/10.4081/ejtm.2024.12811
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.